86 Morris Avenue
BUILDING FOR SUCCESS
Celgene Corporation is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving profitability are marketed products, which include THALOMID (thalidomide), ALKERAN (melphalan), Focalin™, cellular and tissue therapeutics, as well as the Ritalin family of drugs.
Celgene, as a leader in global biotechnology, has built a meaningfully integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based therapies and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.
RECENT PIPELINE HIGHLIGHTS
REVIMID: In February 2003 and April 2003, REVIMID received fast track designation from the FDA for the treatment of multiple myeloma and myelodysplastic syndromes, respectively. REVIMID is currently being tested in two pivotal Phase III FDA SPA trials for the treatment of multiple myeloma and metastatic melanoma. Furthermore, in May, at the International Myelodysplastic Syndromes meeting in Paris, France, REVIMID was the highlight of a study demonstrating medically meaningful erythroid and cytogenic response in MDS patients. That study, initiated by Dr. Alan List of the Moffitt Cancer Center, Tampa Florida, provided the foundation for Celgene to accelerate the potential approval of REVIMID by initiating four Phase II clinical trials; two multicenter Phase II studies in red blood cell transfusion dependent subjects with MDS with or without an associated 5Q minus cytogenetic abnormality and one phase II study in multiple myeloma.
THALOMID: Clinical investigators from leading cancer research centers around the world presented clinical data on THALOMID (thalidomide) in a broad range of hematological malignancies and solid tumor cancers at the Ninth Multiple Myeloma Workshop in Salamanca, Spain and at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, respectively. Several highlighted presentations provided new information on the potential of THALOMID across all stages of multiple myeloma as well as a wide range of solid tumor cancers, including renal cell carcinoma, prostate cancer and malignant melanoma.
ACTIMID™: Our next high-potential orally administered IMiD, is being evaluated in a Phase I/II clinical trial in refractory multiple myeloma and Phase II clinical trial in Prostate cancer. Interim data from an ongoing Phase I/II trial of ACTIMID in 18 relapsed and refractory multiple myeloma patients indicates that ACTIMID has anti-tumor activity in multiple myeloma and has an acceptable toxicity profile.
John W. Jackson - Executive Chairman
Sol J. Barer - Chief Executive Officer
Robert J. Hugin - President and Chief Operating Officer
852 articles with Celgene
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
President Donald Trump was able to claim a victory in the drug pricing wars after Pfizer announced it would walk back the price increase of 40 prescription medications announced earlier this month.
Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative breast cancer (TNBC)
Celgene Corporation announced that its Phase III IMpassion130 trial, sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).
Celgene Corporation and Acceleron Pharma indicated their Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.
Orchard Therapeutics, today announced the appointment of Joanne Beck, Ph.D., to its board of directors.
Because of the potential for significant side effects of CAR-T therapies, the FDA requires Risk Evaluation and Mitigation Strategies (REMS) programs. The Bezos Family Immunotherapy Clinic at the Seattle Cancer Care Alliance is one of those approved sites.
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE).
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
It’s time for some pharmaceutical prognostication. EvaluatePharma released its forward-looking report to 2024 that includes predictions of the best-selling prescription drugs.
The president’s predictions for lower drug prices fell on deaf ears at pharma giant Pfizer as it was reported that the company increased the price of 40 of its most popularly-prescribed medications by nearly 10 percent.
EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT
Evotec AG today announced that the strategic transaction to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.
Roche announced that its Phase III IMpassion130 clinical trial met its co-primary endpoint of progression-free survival (PFS) in triple-negative breast cancer (TNBC).
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Celgene Corporation will host a conference call and live audio webcast on Thursday, July 26, 2018 at 9 a.m. ET to discuss second quarter 2018 financial and operational results.
Acceleron Pharma plans to seek regulatory approval next year for its investigational drug luspatercept. The treatment hit its Phase III endpoints.
Millendo Therapeutics Appoints Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions
Millendo Therapeutics, Inc. today announced the appointment of Ryan Zeidan, Ph.D., as Senior Vice President, Development.